Researchers have developed a deep learning model that can spot longitudinal changes in patients' brain imaging that could be indicative of cancer recurrence.
Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways.
Reviewing data from more than 6,000 patients, researchers found little evidence of the "obesity paradox" observed elsewhere. Underweight TAVR patients, however, may face some significant long-term risks.
The Millipede 088 was designed to treat large vessel occlusion stroke patients by “ingesting” the blood clot as opposed to dragging it through the patient’s blood vessels.
India-based Meril Life Sciences has been manufacturing its Myval transcatheter heart valves for years, but the technology has not yet gained FDA approval. This latest head-to-head comparison included data from more than 1,000 TAVR patients.
“For decades, the patients in our group have testified that they don’t feel they’ve recovered, and we hope our study will provide further clues about what happens in the brain,” experts involved in the study said.
The new guideline calls for a “stepwise approach," followed by close clinical surveillance, when treating uncomplicated TBAD. In some cases, however, earlier endovascular treatments may be necessary.
